发明名称 |
FGFR1 antibodies and treatment of cancer |
摘要 |
The use of an FGFR1 antibody in the treatment of cancer is disclosed, wherein the FGFR1 antibody binds FGFR1 at an epitope that is positioned in the FGFR1 primary amino acid sequence no more than 50 contiguous amino acids away from the C- or N-terminal of the FGFR1 heparin binding domain. |
申请公布号 |
US9333257(B2) |
申请公布日期 |
2016.05.10 |
申请号 |
US201214004913 |
申请日期 |
2012.03.14 |
申请人 |
Agency for Science, Technology and Research |
发明人 |
Cool Simon;Nurcombe Victor;Ling Ling |
分类号 |
A61K39/395;C07K16/28 |
主分类号 |
A61K39/395 |
代理机构 |
Choate, Hall & Stewart LLP |
代理人 |
Choate, Hall & Stewart LLP ;Lyon Charles E.;Vetter Michael L. |
主权项 |
1. A method of treating a cancer in a subject in need of treatment, the method comprising administering an FGFR1 antibody to the subject, wherein the FGFR1 antibody binds FGFR1 at an epitope consisting of an amino acid sequence having less than 20 amino acids and at least 8 contiguous amino acids of the amino acid sequence SSSEEKETDNTKPNR [SEQ ID NO:2], and wherein cells in the cancer express FGFR1 on the cell surface. |
地址 |
Singapore SG |